Shangfeng Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shangfeng Gao has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Rutong Yu
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China
15 shared publications Tong Zhang
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou 221002, China
6 shared publicationsDaofei Ji
Department of Neurosurgery, The Second Affiliated Hospital of Xuzhou Medical University, 32 Mei-Jian Road, Xuzhou, 221006, China
5 shared publicationsFangting You
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou 221002, China; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
4 shared publicationsQingming Meng
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou 221002, China
4 shared publicationsCheng Li
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou 221002, China; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (1) , 47
The atypical kinase right open reading frame kinase 1 suppresses glioma cell growth through mammalian target of rapamycin inhibition and apoptotic signaling activation
Background: Gliomas account for the most frequent malignant neoplasms in the central nervous system (CNS). Though there have been developments in therapeutic approaches, the survival rate for most patients remains poor. This research aimed to explore the clinical importance and underlying mechanism of the atypical kinase right open reading frame kinase 1 (RIOK1) in the growth and proliferation of gliomas. Methods: Differential expression analysis and survival analysis were assessed in public glioma datasets. The levels of RIOK1 protein expression in glioma tissues and non-tumor brain tissues were assessed via Western blot and immunohistochemical analysis. Cell Counting Kit-8 (CCK8) and 5-ethynyl-2'-deoxyuridine (EdU) assays were employed to evaluate glioma cell proliferation. Living cell imaging technology was applied to explore the impact of RIOK1 upregulation on glioma cell proliferative capacity under hypoxic conditions. Protein levels of selected protein kinase B/mammalian target of rapamycin (Akt/mTOR) pathway and apoptosis-related signaling members were evaluated using Western blot. Finally, glioma xenograft models were established to investigate the effect of RIOK1 on glioma tumorigenesis in vivo. Results: We observed a significant downregulation of RIOK1 in isocitrate dehydrogenase (IDH) wild-type gliomas relative to IDH mutant-type gliomas. Compared to non-tumor brain tissues, glioma tissues exhibited a significant reduction in RIOK1 expression levels. Furthermore, overexpression of RIOK1 curbed the growth and proliferation of glioma cells, while downregulation of RIOK1 showed the opposite role. Hypoxia induced decreased expression of RIOK1, which was accompanied by elevated expression of hypoxia-inducible factor 1α (HIF-1α). Under hypoxic conditions, overexpression of RIOK1 inhibited the growth of glioma cells as well. Mechanistically, overexpression of RIOK1 diminished mTOR signaling pathway activity while boosting the activity of apoptosis-related signaling. In vivo, RIOK1 downregulation promotes glioma growth. Conclusions: RIOK1 expression is lower in glioma tissues than in non-tumor brain tissues, and is particularly lower in IDH wild-type gliomas. RIOK1 functions as a suppressor of glioma cell survival and proliferation, possibly through mTOR pathway inhibition and apoptotic pathway activation.
- 1 January 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (1) , 47
Open AccessThe atypical kinase right open reading frame kinase 1 suppresses glioma cell growth through mammalian target of rapamycin inhibition and apoptotic signaling activation
Background: Gliomas account for the most frequent malignant neoplasms in the central nervous system (CNS). Though there have been developments in therapeutic approaches, the survival rate for most patients remains poor. This research aimed to explore the clinical importance and underlying mechanism of the atypical kinase right open reading frame kinase 1 (RIOK1) in the growth and proliferation of gliomas. Methods: Differential expression analysis and survival analysis were assessed in public glioma datasets. The levels of RIOK1 protein expression in glioma tissues and non-tumor brain tissues were assessed via Western blot and immunohistochemical analysis. Cell Counting Kit-8 (CCK8) and 5-ethynyl-2'-deoxyuridine (EdU) assays were employed to evaluate glioma cell proliferation. Living cell imaging technology was applied to explore the impact of RIOK1 upregulation on glioma cell proliferative capacity under hypoxic conditions. Protein levels of selected protein kinase B/mammalian target of rapamycin (Akt/mTOR) pathway and apoptosis-related signaling members were evaluated using Western blot. Finally, glioma xenograft models were established to investigate the effect of RIOK1 on glioma tumorigenesis in vivo. Results: We observed a significant downregulation of RIOK1 in isocitrate dehydrogenase (IDH) wild-type gliomas relative to IDH mutant-type gliomas. Compared to non-tumor brain tissues, glioma tissues exhibited a significant reduction in RIOK1 expression levels. Furthermore, overexpression of RIOK1 curbed the growth and proliferation of glioma cells, while downregulation of RIOK1 showed the opposite role. Hypoxia induced decreased expression of RIOK1, which was accompanied by elevated expression of hypoxia-inducible factor 1α (HIF-1α). Under hypoxic conditions, overexpression of RIOK1 inhibited the growth of glioma cells as well. Mechanistically, overexpression of RIOK1 diminished mTOR signaling pathway activity while boosting the activity of apoptosis-related signaling. In vivo, RIOK1 downregulation promotes glioma growth. Conclusions: RIOK1 expression is lower in glioma tissues than in non-tumor brain tissues, and is particularly lower in IDH wild-type gliomas. RIOK1 functions as a suppressor of glioma cell survival and proliferation, possibly through mTOR pathway inhibition and apoptotic pathway activation.
- Open Access
- 23 October 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-13
The WW domain presents a promising target for the development of PCIF1 agonists in the treatment of glioma
PCIF1 is currently the sole m6Am methyltransferase in mammalian mRNA, but it was initially named for the interaction between its WW domain and RNA polymerase II. Emerging studies reveal the important role of PCIF1 in the progression of various cancers, particularly highlighting its methyltransferase activity. Recently, we found that PCIF1 effectively inhibited the growth of gliomas both in vitro and in vivo. Notably, this inhibition was not entirely dependent on its methyltransferase activity. In this study, we found that the deletion or mutation of the WW domain reversed the inhibitory effect of PCIF1 on cell proliferation in both PCIF1 wild-type and knockout glioma cells. Overexpression of the WW domain of PCIF1 alone significantly inhibited glioma cell proliferation without notable effects on normal astrocytes, and this inhibition was more pronounced when the WW domain was localized to the nucleus. Introduction of an exogenous WW domain reduced PCIF1 protein stability, subsequently diminishing its interaction with RNA Polymerase II. Mechanistically, forced expression of the WW domain into the nucleus facilitated the translocation of endogenous PCIF1 from the nucleus to the cytoplasm and promoted its degradation through the ubiquitin-proteasome system and the autophagy-lysosomal pathway. In addition, overexpression of the WW domain of PCIF1 inhibited the growth of gliomas and extended the survival of tumor-bearing mice. These data indicate that the WW domain plays a crucial role in PCIF1-mediated inhibition of glioma cell growth and presents a promising target for the development of PCIF1 agonists in glioma treatment.
- 23 October 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-13
Open AccessThe WW domain presents a promising target for the development of PCIF1 agonists in the treatment of glioma
PCIF1 is currently the sole m6Am methyltransferase in mammalian mRNA, but it was initially named for the interaction between its WW domain and RNA polymerase II. Emerging studies reveal the important role of PCIF1 in the progression of various cancers, particularly highlighting its methyltransferase activity. Recently, we found that PCIF1 effectively inhibited the growth of gliomas both in vitro and in vivo. Notably, this inhibition was not entirely dependent on its methyltransferase activity. In this study, we found that the deletion or mutation of the WW domain reversed the inhibitory effect of PCIF1 on cell proliferation in both PCIF1 wild-type and knockout glioma cells. Overexpression of the WW domain of PCIF1 alone significantly inhibited glioma cell proliferation without notable effects on normal astrocytes, and this inhibition was more pronounced when the WW domain was localized to the nucleus. Introduction of an exogenous WW domain reduced PCIF1 protein stability, subsequently diminishing its interaction with RNA Polymerase II. Mechanistically, forced expression of the WW domain into the nucleus facilitated the translocation of endogenous PCIF1 from the nucleus to the cytoplasm and promoted its degradation through the ubiquitin-proteasome system and the autophagy-lysosomal pathway. In addition, overexpression of the WW domain of PCIF1 inhibited the growth of gliomas and extended the survival of tumor-bearing mice. These data indicate that the WW domain plays a crucial role in PCIF1-mediated inhibition of glioma cell growth and presents a promising target for the development of PCIF1 agonists in glioma treatment.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 625-638
Application of Multifunctional Metal Nanoparticles in the Treatment of Glioma
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. The current review aims to systematically summarize the application of different types of metal nanoparticles in the treatment and detection of glioma. We also discussed the advantages and mechanisms of metal nanoparticles when used for glioma therapy, including chemotherapy, radiotherapy and photothermal therapy. We hope to promote the application of metallic nanoparticles in glioma diagnosis and treatment, moving towards clinical translation to benefit patients.
- 1 January 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 625-638
Open AccessApplication of Multifunctional Metal Nanoparticles in the Treatment of Glioma
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. The current review aims to systematically summarize the application of different types of metal nanoparticles in the treatment and detection of glioma. We also discussed the advantages and mechanisms of metal nanoparticles when used for glioma therapy, including chemotherapy, radiotherapy and photothermal therapy. We hope to promote the application of metallic nanoparticles in glioma diagnosis and treatment, moving towards clinical translation to benefit patients.
- 9 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217114
Gender differences in gliomas: From epidemiological trends to changes at the hormonal and molecular levels
- 9 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217114
Gender differences in gliomas: From epidemiological trends to changes at the hormonal and molecular levels
- Open Access
- 5 December 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1304224
Construction and validation of a risk model based on the key SNARE proteins to predict the prognosis and immune microenvironment of gliomas
Background: Synaptic transmission between neurons and glioma cells can promote glioma progression. The soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptors (SNARE) play a key role in synaptic functions. We aimed to construct and validate a novel model based on the SNARE proteins to predict the prognosis and immune microenvironment of glioma.Methods: Differential expression analysis and COX regression analysis were used to identify key SRGs in glioma datasets, and we constructed a prognostic risk model based on the key SRGs. The prognostic value and predictive performance of the model were assessed in The Cancer Genome Atlas (TCGA) and Chinese glioma Genome Atlas (CGGA) datasets. Functional enrichment analysis and immune-related evaluation were employed to reveal the association of risk scores with tumor progression and microenvironment. A prognostic nomogram containing the risk score was established and assessed by calibration curves and time-dependent receiver operating characteristic curves. We verified the changes of the key SRGs in glioma specimens and cells by real-time quantitative PCR and Western blot analyses.Results: Vesicle-associated membrane protein 2 (VAMP2) and vesicle-associated membrane protein 5 (VAMP5) were identified as two SRGs affecting the prognoses of glioma patients. High-risk patients characterized by higher VAMP5 and lower VAMP2 expression had a worse prognosis. Higher risk scores were associated with older age, higher tumor grades, IDH wild-type, and 1p19q non-codeletion. The SRGs risk model showed an excellent predictive performance in predicting the prognosis in TCGA and CGGA datasets. Differentially expressed genes between low- and high-risk groups were mainly enriched in the pathways related to immune infiltration, tumor metastasis, and neuronal activity. Immune score, stromal score, estimate score, tumor mutational burden, and expression of checkpoint genes were positively correlated with risk scores. The nomogram containing the risk score showed good performance in predicting the prognosis of glioma. Low VAMP2 and high VAMP5 were found in different grades of glioma specimens and cell lines.Conclusion: We constructed and validated a novel risk model based on the expression of VAMP2 and VAMP5 by bioinformatics analysis and experimental confirmation. This model might be helpful for clinically predicting the prognosis and response to immunotherapy of glioma patients.
- 5 December 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1304224
Open AccessConstruction and validation of a risk model based on the key SNARE proteins to predict the prognosis and immune microenvironment of gliomas
Background: Synaptic transmission between neurons and glioma cells can promote glioma progression. The soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptors (SNARE) play a key role in synaptic functions. We aimed to construct and validate a novel model based on the SNARE proteins to predict the prognosis and immune microenvironment of glioma.Methods: Differential expression analysis and COX regression analysis were used to identify key SRGs in glioma datasets, and we constructed a prognostic risk model based on the key SRGs. The prognostic value and predictive performance of the model were assessed in The Cancer Genome Atlas (TCGA) and Chinese glioma Genome Atlas (CGGA) datasets. Functional enrichment analysis and immune-related evaluation were employed to reveal the association of risk scores with tumor progression and microenvironment. A prognostic nomogram containing the risk score was established and assessed by calibration curves and time-dependent receiver operating characteristic curves. We verified the changes of the key SRGs in glioma specimens and cells by real-time quantitative PCR and Western blot analyses.Results: Vesicle-associated membrane protein 2 (VAMP2) and vesicle-associated membrane protein 5 (VAMP5) were identified as two SRGs affecting the prognoses of glioma patients. High-risk patients characterized by higher VAMP5 and lower VAMP2 expression had a worse prognosis. Higher risk scores were associated with older age, higher tumor grades, IDH wild-type, and 1p19q non-codeletion. The SRGs risk model showed an excellent predictive performance in predicting the prognosis in TCGA and CGGA datasets. Differentially expressed genes between low- and high-risk groups were mainly enriched in the pathways related to immune infiltration, tumor metastasis, and neuronal activity. Immune score, stromal score, estimate score, tumor mutational burden, and expression of checkpoint genes were positively correlated with risk scores. The nomogram containing the risk score showed good performance in predicting the prognosis of glioma. Low VAMP2 and high VAMP5 were found in different grades of glioma specimens and cell lines.Conclusion: We constructed and validated a novel risk model based on the expression of VAMP2 and VAMP5 by bioinformatics analysis and experimental confirmation. This model might be helpful for clinically predicting the prognosis and response to immunotherapy of glioma patients.
- Open Access
- 24 March 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 162, 114555
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
- 24 March 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 162, 114555
Open AccessSitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
- Open Access
- 28 February 2023
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (1) , 139-156
Research progress in molecular pathology markers in medulloblastoma
Medulloblastoma (MB) is the commonest primary malignant brain cancer. The current treatment of MB is usually surgical resection combined with radiotherapy or chemotherapy. Although great progress has been made in the clinical management of MB, tumor metastasis and recurrence are still the main cause of death. Therefore, definitive and timely diagnosis is of great importance for improving therapeutic effects on MB. In 2016, the World Health Organization (WHO) divided MB into four subtypes: wingless-type mouse mammary tumor virus integration site (WNT), sonic hedgehog (SHH), non-WNT/non-SHH group 3, and group 4. Each subtype of MB has a unique profile in copy number variation, DNA alteration, gene transcription, or post-transcriptional/translational modification, all of which are associated with different biological manifestations, clinical features, and prognosis. This article reviewed the research progress of different molecular pathology markers in MB and summarized some targeted drugs against these molecular markers, hoping to stimulate the clinical application of these molecular markers in the classification, diagnosis, and treatment of MB.
- 28 February 2023
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (1) , 139-156
Open AccessResearch progress in molecular pathology markers in medulloblastoma
Medulloblastoma (MB) is the commonest primary malignant brain cancer. The current treatment of MB is usually surgical resection combined with radiotherapy or chemotherapy. Although great progress has been made in the clinical management of MB, tumor metastasis and recurrence are still the main cause of death. Therefore, definitive and timely diagnosis is of great importance for improving therapeutic effects on MB. In 2016, the World Health Organization (WHO) divided MB into four subtypes: wingless-type mouse mammary tumor virus integration site (WNT), sonic hedgehog (SHH), non-WNT/non-SHH group 3, and group 4. Each subtype of MB has a unique profile in copy number variation, DNA alteration, gene transcription, or post-transcriptional/translational modification, all of which are associated with different biological manifestations, clinical features, and prognosis. This article reviewed the research progress of different molecular pathology markers in MB and summarized some targeted drugs against these molecular markers, hoping to stimulate the clinical application of these molecular markers in the classification, diagnosis, and treatment of MB.
- Open Access
- 1 February 2022
- Published by Elsevier in Cancer Letters
- Vol. 527, 140-149
Drug repositioning: Using psychotropic drugs for the treatment of glioma
- 1 February 2022
- Published by Elsevier in Cancer Letters
- Vol. 527, 140-149
Open AccessDrug repositioning: Using psychotropic drugs for the treatment of glioma
- 1 December 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 194, 114795
A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway
- 1 December 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 194, 114795
A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway
- 11 December 2020
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 37 (5) , 1074-1077
The value of texture analysis in peritumoral edema of differentiating diagnosis between glioblastoma and primary brain lymphoma
To evaluate the value of texture analysis of routine MRI image in peritumoral edema of differentiating diagnosis between glioblastoma (GBM) and primary brain lymphoma (PBL). The MRI imaging data of...
- 11 December 2020
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 37 (5) , 1074-1077
The value of texture analysis in peritumoral edema of differentiating diagnosis between glioblastoma and primary brain lymphoma
To evaluate the value of texture analysis of routine MRI image in peritumoral edema of differentiating diagnosis between glioblastoma (GBM) and primary brain lymphoma (PBL). The MRI imaging data of...